Deerfield Management formed Boulevard Bio with scientific co-founders Georg Schett and Frank Nestle. The startup’s lead program is in early clinical development for an autoimmune kidney disorder, and could offer dosing advantages over a recently approved Vera Therapeutics medicine and a Vertex Pharmaceuticals drug currently under FDA review.
The post Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder appeared first on MedCity News.
